Latest research on Olmesartan medoxomil

Olmesartan is an antihypertensive agent, which belongs to the class of medications called angiotensin II receptor blockers. It is indicated for the treatment of high blood pressure and is marketed under the name Olmetec®. The FDA label includes a black-box warning of injury and death to the fetus, so women of child-bearing age need to be warned and take the necessary precautions. Olmesartan is also contraindicated in diabetes mellitus patients taking aliskiren.

Latest findings

Antihypertensive drug treatment was then uptitrated at 4-week intervals until goal BP was achieved, progressing through the following steps: uptitration to Olmesartan medoxomil 40 mg/day, addition of HCTZ 12.5 mg/day, uptitration of HCTZ to 25 mg/day, addition of Amlodipine besylate 5 mg/day, and then uptitration of Amlodipine besylate to 10 mg/day (Neutel et al 2004, 2006). [source, 2006]
The results of this study showed that a BP goal of ≤140/90 mmHg and a more aggressive BP goal of ≤130/85 mmHg could be achieved in many patients using a combination of Olmesartan medoxomil and HCTZ (Neutel et al 2004, 2006). [source, 2006]
In this randomized, double-blind, multicenter trial, patients were treated with starting doses of each ARB (Olmesartan medoxomil 20 mg/day [n=308] or Losartan 50 mg/day [n=305]) plus HCTZ 12.5 mg/day for 12 weeks. [source, 2006]
In this double-blind, non-inferiority study, 328 patients with a mean seated DBP of 100–120 mmHg receiving HCTZ 25 mg/day were randomized to receive Olmesartan medoxomil 10 mg/day or Atenolol 50 mg/day in addition to the HCTZ dose for 12 weeks, with dose-doubling after 4 weeks, if necessary. [source, 2006]
Looking first at the individual components, an integrated analysis of efficacy and safety demonstrated that the adverse events profile observed with Olmesartan medoxomil monotherapy is similar to that seen with placebo, with dizziness the only adverse event to occur in a significantly greater number of Olmesartan medoxomil patients compared with placebo (2.8% vs 0.9%, respectively, p=0.01) (Neutel 2001). [source, 2006]
Adverse events associated with the combination of Olmesartan medoxomil plus HCTZ are generally mild-to-moderate in severity (Ball et al 2001; Chrysant et al 2004; Neutel et al 2004; Rump et al 2006). [source, 2006]